Posted by Michael Wonder on 11 Dec 2024
Delgocitinib approved to treat adult patients with moderate to severe chronic hand eczema
10 December 2024 - The MHRA has approved the medicine delgocitinib (Anzupgo) to treat moderate to severe chronic hand eczema in adults when topical corticosteroids are inadequate or inappropriate.
The new marketing authorisation was granted in 59 days on 29 November 2024 to Leo Pharma under the International Recognition Procedure Route B.
